Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Hematology. 2023 Dec;28(1):2284047. doi: 10.1080/16078454.2023.2284047. Epub 2023 Nov 27.
The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL.
A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates.
From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea.
For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.
皮下注射利妥昔单抗在非霍奇金淋巴瘤（NHL）中的疗效和安全性尚不清楚。本研究旨在进行系统评价和荟萃分析，以评估皮下注射利妥昔单抗治疗 NHL 的疗效和安全性。
根据设定的检索词，在 PubMed、Web of Science、Embase 和 Cochrane CENTRAL 中进行全面检索，检索时间截至 2022 年 10 月 12 日，以确定关于皮下注射利妥昔单抗治疗 NHL 的相关研究。疗效和安全性结局包括完全缓解（CR）加不确定的完全缓解（CRu）、不良事件（AE）、≥3 级 AE、严重不良事件（SAE）、与给药相关的反应（ARR）、不良反应发生率。
共检索到 758 篇文献，其中 9 项研究符合纳入标准。接受皮下注射利妥昔单抗的 NHL 患者的 CR/CRu 为 57%，弥漫性大 B 细胞淋巴瘤（DLBCL）为 55%，滤泡性淋巴瘤（FL）为 54%。对安全性进行的荟萃分析表明，接受皮下注射利妥昔单抗的 NHL 患者的 AE 发生率为 85%，≥3 级 AE 发生率为 38%，SAE 发生率为 27%，ARR 发生率为 33%。结果还显示，皮下注射利妥昔单抗有发生中性粒细胞减少和恶心的高风险。
对于 NHL 患者，皮下注射利妥昔单抗与常规治疗的疗效无显著差异，而皮下注射可缩短住院时的暴露时间，并降低感染风险。
